​

Aclaris Therapeutics (ACRS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ACRS Stock Forecast

Aclaris Therapeutics (ACRS) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $10.60, with a high of $12.00 and a low of $10.00. This represents a 142.56% increase from the last price of $4.37.

- $3 $6 $9 $12 $15 High: $12 Avg: $10.6 Low: $10 Last Closed Price: $4.37

ACRS Stock Rating

Aclaris Therapeutics stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (81.25%), 3 Hold (18.75%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 3 13 Strong Sell Sell Hold Buy Strong Buy

ACRS Price Target Upside V Benchmarks

TypeNameUpside
StockAclaris Therapeutics142.56%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-45
Avg Price Target-$10.75$10.60
Last Closing Price$4.37$4.37$4.37
Upside/Downside-146.00%142.56%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26181--10
May, 26171--9
Apr, 26161--8
Mar, 26161--8
Feb, 26161--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 05, 2026Biren AminPiper Sandler$11.00$4.53142.83%151.72%
May 05, 2026Guggenheim$12.00$4.53164.90%174.60%
Apr 29, 2026Martin FanWedbush$10.00$4.22136.97%128.83%
Apr 16, 2026UBS$10.00$3.93154.45%128.83%
Jan 30, 2026Adam VogelCraig-Hallum$10.00$3.43191.55%128.83%
Nov 19, 2024Julian HarrisonBTIG$8.00$3.14154.78%83.07%
Nov 19, 2024Roger SongJefferies$7.00$3.14122.93%60.18%
Nov 06, 2024Alex ThompsonStifel Nicolaus$3.00$2.2831.58%-31.35%
Dec 01, 2022Goldman Sachs$25.00$15.2264.26%472.08%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 05, 2026Piper SandlerOverweightOverweighthold
May 05, 2026GuggenheimBuyinitialise
Apr 29, 2026WedbushOutperformOutperformhold
Apr 16, 2026OppenheimerOutperforminitialise
Jan 30, 2026Craig-HallumBuyinitialise
Jan 28, 2026CitigroupBuyBuyhold
Jan 06, 2026JefferiesBuyBuyhold
May 28, 2025WedbushOutperforminitialise
May 14, 2025H.C. WainwrightBuyBuyhold
Mar 07, 2025ScotiabankOutperforminitialise

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.60$-1.33$-1.27$-1.71$-0.53---
Avg Forecast$-1.61$-1.44$-1.61$-0.82$-0.59$-0.65$-0.71$-0.59
High Forecast$-0.33$-0.31$-1.52$-0.57$-0.45$-0.49$-0.60$0.02
Low Forecast$-3.90$-3.76$-1.66$-1.12$-0.99$-0.94$-0.86$-1.28
Surprise %-0.62%-7.64%-21.12%108.54%-10.17%---

Revenue Forecast

$0 $17M $34M $51M $68M $85M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.76M$29.75M$31.25M$18.72M$7.83M---
Avg Forecast$7.05M$23.99M$18.34M$11.62M$11.97M$8.29M$6.96M$42.43M
High Forecast$14.78M$53.87M$24.25M$13.77M$21.72M$15.66M$13.14M$80.13M
Low Forecast$2.73M$9.48M$14.96M$10.06M$2.80M$1.74M$1.46M$8.90M
Surprise %-4.13%24.00%70.40%61.15%-34.63%---

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-90.86M$-86.91M$-88.48M$-132.06M$-64.92M---
Avg Forecast$-77.55M$-87.16M$-88.48M$-58.98M$-61.52M$-49.98M$-50.91M$-41.42M
High Forecast$-62.04M$-69.73M$-70.78M$-39.55M$-31.59M$-34.03M$-42.02M$1.13M
Low Forecast$-93.06M$-104.59M$-106.18M$-78.40M$-68.80M$-65.94M$-59.80M$-89.27M
Surprise %17.16%-0.28%-123.93%5.54%---

ACRS Forecast FAQ

Is Aclaris Therapeutics stock a buy?

Aclaris Therapeutics stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Aclaris Therapeutics is a favorable investment for most analysts.

What is Aclaris Therapeutics's price target?

Aclaris Therapeutics's price target, set by 16 Wall Street analysts, averages $10.6 over the next 12 months. The price target range spans from $10 at the low end to $12 at the high end, suggesting a potential 142.56% change from the previous closing price of $4.37.

How does Aclaris Therapeutics stock forecast compare to its benchmarks?

Aclaris Therapeutics's stock forecast shows a 142.56% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Aclaris Therapeutics over the past three months?

  • June 2026: 10.00% Strong Buy, 80.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 11.11% Strong Buy, 77.78% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 12.50% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Aclaris Therapeutics’s EPS forecast?

Aclaris Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.65, marking a 22.64% increase from the reported $-0.53 in 2025. Estimates for the following years are $-0.71 in 2027, and $-0.59 in 2028.

What is Aclaris Therapeutics’s revenue forecast?

Aclaris Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $8.29M, reflecting a 5.99% increase from the reported $7.83M in 2025. The forecast for 2027 is $6.96M, and $42.43M for 2028.

What is Aclaris Therapeutics’s net income forecast?

Aclaris Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-49.984M, representing a -23.01% decrease from the reported $-64.923M in 2025. Projections indicate $-50.912M in 2027, and $-41.42M in 2028.